Literature DB >> 22630149

Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine.

Dodi Safari1, Marco Marradi, Fabrizio Chiodo, Huberta A Th Dekker, Yulong Shan, Roberto Adamo, Stefan Oscarson, Ger T Rijkers, Martina Lahmann, Johannis P Kamerling, Soledad Penadés, Harm Snippe.   

Abstract

AIMS: Coupling of capsular polysaccharides of pathogens to immunogenic protein carriers (conjugate vaccines) improves carbohydrate immune response. Our idea is to explore gold nanoclusters as carriers to prepare fully synthetic carbohydrate vaccines. MATERIALS &
METHODS: Gold glyconanoparticles bearing a synthetic tetrasaccharide epitope related to the Streptococcus pneumoniae type 14 capsular polysaccharide (Pn14PS), the T-helper ovalbumin 323-339 peptide (OVA(323-339)), and D-glucose were prepared by a one-pot method. Their immunogenicity was tested in mice. Cytokine levels after spleen cell stimulation with OVA(323-339) were analyzed using a luminex-multiplex cytokine assay. The capacity of the evoked antibodies to promote the uptake of S. pneumoniae type 14 by leukocytes was assessed. RESULTS & DISCUSSION: Glyconanoparticles containing 45% of tetrasaccharide and 5% OVA(323-339) triggered specific anti-Pn14PS IgG antibodies. Cytokine levels confirmed that glyconanoparticles led to T-helper cell activation. The anti-saccharide antibodies promoted the phagocytosis of type 14 bacteria by human leukocytes, indicating the functionality of the antibodies.
CONCLUSION: Gold nanoparticles have great potential as carriers for the development of a great diversity of fully synthetic carbohydrate-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22630149     DOI: 10.2217/nnm.11.151

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  37 in total

Review 1.  Applications and perspectives of nanomaterials in novel vaccine development.

Authors:  Yingbin Shen; Tianyao Hao; Shiyi Ou; Churan Hu; Long Chen
Journal:  Medchemcomm       Date:  2017-10-17       Impact factor: 3.597

2.  Pre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanoma.

Authors:  Hector Terán-Navarro; Ricardo Calderon-Gonzalez; David Salcines-Cuevas; Isabel García; Marco Marradi; Javier Freire; Erwan Salmon; Mar Portillo-Gonzalez; Elisabet Frande-Cabanes; Almudena García-Castaño; Virginia Martinez-Callejo; Javier Gomez-Roman; Raquel Tobes; Fernando Rivera; Sonsoles Yañez-Diaz; Carmen Álvarez-Domínguez
Journal:  Oncoimmunology       Date:  2018-11-10       Impact factor: 8.110

3.  Electrically Oscillating Plasmonic Nanoparticles for Enhanced DNA Vaccination against Hepatitis C Virus.

Authors:  Mohamed Shehata Draz; Ying-Jie Wang; Frank Fanqing Chen; Yuhong Xu; Hadi Shafiee
Journal:  Adv Funct Mater       Date:  2016-12-14       Impact factor: 18.808

Review 4.  Clustered carbohydrates in synthetic vaccines.

Authors:  Francesco Peri
Journal:  Chem Soc Rev       Date:  2012-12-18       Impact factor: 54.564

Review 5.  Multivalent glycoconjugates as anti-pathogenic agents.

Authors:  Anna Bernardi; Jesus Jiménez-Barbero; Alessandro Casnati; Cristina De Castro; Tamis Darbre; Franck Fieschi; Jukka Finne; Horst Funken; Karl-Erich Jaeger; Martina Lahmann; Thisbe K Lindhorst; Marco Marradi; Paul Messner; Antonio Molinaro; Paul V Murphy; Cristina Nativi; Stefan Oscarson; Soledad Penadés; Francesco Peri; Roland J Pieters; Olivier Renaudet; Jean-Louis Reymond; Barbara Richichi; Javier Rojo; Francesco Sansone; Christina Schäffer; W Bruce Turnbull; Trinidad Velasco-Torrijos; Sébastien Vidal; Stéphane Vincent; Tom Wennekes; Han Zuilhof; Anne Imberty
Journal:  Chem Soc Rev       Date:  2012-12-19       Impact factor: 54.564

6.  Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.

Authors:  Shannon L Haughney; Latrisha K Petersen; Amy D Schoofs; Amanda E Ramer-Tait; Janice D King; David E Briles; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2013-06-14       Impact factor: 8.947

Review 7.  Recent advances in synthetic carbohydrate-based human immunodeficiency virus vaccines.

Authors:  Zhenyuan Wang; Chunjun Qin; Jing Hu; Xiaoqiang Guo; Jian Yin
Journal:  Virol Sin       Date:  2016-03-17       Impact factor: 4.327

8.  Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.

Authors:  Zachary R Sia; Matthew S Miller; Jonathan F Lovell
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

Review 9.  Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.

Authors:  Christopher D Spicer; Coline Jumeaux; Bakul Gupta; Molly M Stevens
Journal:  Chem Soc Rev       Date:  2018-05-21       Impact factor: 54.564

Review 10.  Gold nanoparticle mediated cancer immunotherapy.

Authors:  Joao Paulo Mattos Almeida; Elizabeth Raquel Figueroa; Rebekah Anna Drezek
Journal:  Nanomedicine       Date:  2013-10-05       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.